H.C. Wainwright downgraded 89bio (ETNB) to Neutral from Buy with a price target of $14.50, down from $32, after the company entered into a merger agreement to be acquired by Roche (RHHBY) for $14.50 per share in cash.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETNB: